GLP-1 Receptor Agonist Prescription Patterns in the All of Us Research Program
This study characterizes the sociodemographic and clinical profiles of 15,477 All of Us participants prescribed GLP-1 receptor agonists, demonstrating that the program's diverse, multi-modal dataset is a robust resource for future real-world research on these rapidly expanding treatments.
Original paper dedicated to the public domain under CC0 1.0 (https://creativecommons.org/publicdomain/zero/1.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Imagine the All of Us Research Program as a massive, digital library of American lives. Instead of just books, this library holds electronic health records, survey answers, genetic data, and even step-counts from smartwatches for over 633,000 volunteers.
This paper is like a librarian walking through a specific aisle of that library to see who is checking out a very popular, fast-growing type of medicine called GLP-1 receptor agonists (often known by brand names like Ozempic, Wegovy, or Mounjaro). These drugs are famous for treating type 2 diabetes and obesity, but scientists are also curious if they help with other things like sleep apnea or heart health.
Here is what the authors found, explained simply:
1. The "Who" in the Library
The researchers looked for people who had been prescribed these drugs at least twice on different days. They found 15,477 people in the library who fit this description.
- The Crowd: Compared to the average person in the library, this group is generally older, has more health problems (like diabetes or high blood pressure), and visits the doctor more often.
- The Demographics: This group includes more women and Black/African American participants than the library's general population, but fewer Asian American or Hispanic/Latino participants.
- The Lifestyle: They tend to have lower incomes and education levels, are more likely to be retired or disabled, and report feeling less healthy overall.
2. The "What" (The Medicine Trends)
The researchers tracked the history of these prescriptions like a timeline on a map:
- The Slow Start: In 2005, when the first drug of this type was approved, there were very few people taking it (less than 20).
- The Explosion: By 2022, the number of people taking these drugs had skyrocketed to over 9,000, with nearly 43,000 prescriptions written that year alone.
- The Favorites:
- Early Days (2005–2012): Most people took exenatide.
- Middle Era (2013–2017): Liraglutide became the most popular.
- Recent Years (2018–2022): Semaglutide (the drug behind Ozempic/Wegovy) took the lead, followed closely by dulaglutide. A newer drug, tirzepatide, just started appearing in 2022.
3. The "How Long" (Sticking with the Plan)
The study looked at how long people stayed on these meds.
- The Average Run: The median time between a person's first and last prescription was about 1.5 years.
- The Hiccups: Many people (about 69%) had a "gap" in their treatment where they stopped taking the drug for more than 90 days. When they did go back on it, the average time between doses was about a month.
- The Episodes: Most people had a few separate "stints" of taking the drug rather than one continuous, unbroken line.
4. The "Data Treasure Chest"
One of the main points of this paper is to show that the All of Us library is a goldmine for studying these drugs.
- Rich Details: For the people taking these drugs, the library has almost everything: 99% have body weight (BMI) records, 99% have blood pressure readings, and nearly 90% have blood test results for things like cholesterol and sugar levels.
- The Smartwatch Bonus: About 12% of these people also wore Fitbits. The researchers checked this data and found that, on average, these people's heart rates went up slightly after they started the medication. This matches what other studies have found, proving the data is reliable.
5. The "Fine Print" (Limitations)
The authors are careful to say this isn't a perfect mirror of the whole United States.
- Volunteer Bias: The people in this library volunteered to be there. They might be more willing to share their health data than the average American.
- Not a National Census: You can't look at these numbers and say, "This is exactly how many people in the whole US are taking these drugs." It's a snapshot of a specific, diverse group, not a national census.
- Missing Pieces: Sometimes, if a patient sees a doctor who isn't connected to the All of Us system, that data is missing. Also, the library knows when a doctor wrote a prescription, but it doesn't always know if the patient actually took the medicine.
The Bottom Line
This paper doesn't tell us if these drugs are "good" or "bad" for new conditions. Instead, it acts as a map and a toolkit. It says: "Hey researchers, we have a huge, diverse group of 15,000 people here with detailed health records, smartwatch data, and long histories of taking these popular drugs. If you want to study how these drugs work in the real world, this is a fantastic place to start."
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.